Together, these data challenge the potential therapeutic utility of TMEM16A blockers for the treatment of respiratory diseases18 and support the evaluation of TMEM16A potentiators as an approach to hydrate mucus in diseases such as CF.5, 6, 7. The gene discussed is ANO1; the disease is cystic fibrosis.